Immunologic effects of the renin-angiotensin system

Journal of the American Society of Nephrology

Volumn 28, Issue 5, 2017, Pages 1350-1361

  Crowley, Steven D ^a   Rudemiller, Nathan P ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE; PRORENIN; RENIN; ANGIOTENSIN I; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT;

ADAPTIVE IMMUNITY; HUMAN; INNATE IMMUNITY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; IMMUNOLOGY; PHYSIOLOGY;

ANGIOTENSIN I; ANIMALS; HUMANS; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RENIN-ANGIOTENSIN SYSTEM;

EID: 85021848940     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016101066     Document Type: Review

References (114)

1. Goldblatt H, Lynch J, Hanzal RF, Summerville WW: Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J ExpMed 59: 347-379, 1934
2. Guyton AC: Blood pressure control-special role of the kidneys and body fluids. Science 252: 1813-1816, 1991
3. Hall JE, Brands MW, Henegar JR: Angiotensin II and long-term arterial pressure regulation: The overriding dominance of the kidney. J AmSocNephrol 10[Suppl 12]: S258-S265, 1999
4. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57: 1803-1817, 2000
5. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
6. MaschioG, Alberti D, JaninG, Locatelli F, Mann JF, MotoleseM, Ponticelli C, Ritz E, Zucchelli P; The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945, 1996
7. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002
8. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM: Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995
9. Oliverio MI, Best CF, Smithies O, Coffman TM: Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II. Hypertension 35: 550-554, 2000
10. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA: Intratubular renin-angiotensin system in hypertension. Hypertension 57: 355-362, 2011
11. Nataraj C, OliverioMI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 104: 1693-1701, 1999
12. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R:Human T and natural killer cells possess a functional renin-angiotensin system: Further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 18: 1093-1102, 2007
13. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 62[Suppl 82]: S12-S22, 2002
14. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 161: 430-439, 1998
15. Guo S, Kowalewska J, Wietecha TA, Iyoda M, Wang L, Yi K, Spencer M, Banas M, Alexandrescu S, Hudkins KL, Alpers CE: Renin-angiotensin system blockade is renoprotective in immune complex-mediated glomerulonephritis. J Am Soc Nephrol 19: 1168-1176, 2008
16. Pérez De Lema G, De Wit C, Cohen CD, Nieto E, Molina A, Banas B, Luckow B, Vicente AB, Mampaso F, Schlöndorff D: Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther 307: 275-281, 2003
17. Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M, Egido J: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95: 1532-1541, 1997
18. Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 31: 181-188, 1998
19. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 92: 1366-1372, 1993
20. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L: Angiotensin II sustains brain inflammation in mice via TGFbeta. J Clin Invest 120: 2782-2794, 2010
21. Agarwal R: Proinflammatory effects of oxidative stress in chronic kidney disease: Role of additional angiotensin II blockade. Am J Physiol Renal Physiol 284: F863-F869, 2003
22. Sparks MA, Stegbauer J, Chen D, Gomez JA, Griffiths RC, Azad HA, HerreraM, Gurley SB, Coffman TM: Vascular type 1A angiotensin II receptors control BP by regulating renal blood flow and urinary sodium excretion. J Am Soc Nephrol 26: 2953-2962, 2015
23. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 103: 17985-17990, 2006
24. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC: Immunosuppressive treatment protects against angiotensin IIinduced renal damage. Am J Pathol 161: 1679-1693, 2002
25. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J ExpMed 204: 2449-2460, 2007
26. Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P: Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 298: R1089-R1097, 2010
27. Franco M, Tapia E, Santamaría J, Zafra I, García-Torres R, Gordon KL, Pons H, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Renal cortical vasoconstriction contributes to development of salt-sensitive hypertension after angiotensin II exposure. J Am Soc Nephrol 12: 2263-2271, 2001
28. KleinewietfeldM, Manzel A, Titze J, Kvakan H, YosefN, Linker RA, MullerDN, Hafler DA: Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 496: 518-522, 2013
29. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T: Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42: 31-38, 2003
30. Ozawa Y, Kobori H, Suzaki Y, Navar LG: Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol 292: F330-F339, 2007
31. Hisada Y, Sugaya T, Tanaka S, Suzuki Y, Ra C, Kimura K, Fukamizu A: An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immunemediated renal injury. Lab Invest 81: 1243-1251, 2001
32. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, Murakami K: Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103: 627-635, 1999
33. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, FosterMH, Coffman TM: Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 119: 943-953, 2009
34. Lu H, Rateri DL, Feldman DL, Charnigo Jr. RJ, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A: Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118: 984-993, 2008
35. Koga J, Egashira K, Matoba T, Kubo M, Ihara Y, Iwai M, Horiuchi M, Sunagawa K: Essential role of angiotensin II type 1a receptors in the host vascular wall, but not the bone marrow, in the pathogenesis of angiotensin II-induced atherosclerosis. Hypertens Res 31: 1791-1800, 2008
36. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, Obst M, Gross V, Dietz R, Luft FC, Scheidereit C, Muller DN: Vascular endothelial cell-specific NFkappaB suppression attenuates hypertension-induced renal damage. Circ Res 101: 268-276, 2007
37. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109: 1417-1427, 2002
38. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C: Requirement of prorenin receptor and vacuolar H+-ATPasemediated acidification for Wnt signaling. Science 327: 459-463, 2010
39. Shi P, Grobe JL, Desland FA, Zhou G, Shen XZ, Shan Z, Liu M, Raizada MK, Sumners C: Direct pro-inflammatory effects of prorenin on microglia. PLoS One 9: E92937, 2014
40. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, FukamizuA, Tsubota K, ItohH, Oike Y, Ishida S: (Pro)renin receptor-mediated signal transduction and tissue reninangiotensin system contribute to diabetesinduced retinal inflammation. Diabetes 58: 1625-1633, 2009
41. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN: Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 51: 682-688, 2008
42. Geisberger S, Maschke U, Gebhardt M, Kleinewietfeld M, Manzel A, Linker RA, Chidgey A, Dechend R, Nguyen G, Daumke O, Muller DN, Wright MD, Binger KJ: New role for the (pro)renin receptor in T-cell development. Blood 126: 504-507, 2015
43. Narumi K, Hirose T, Sato E, Mori T, Kisu K, Ishikawa M, Totsune K, Ishii T, Ichihara A, Nguyen G, Sato H, Ito S: A functional (pro) renin receptor is expressed in human lymphocytes and monocytes. Am J Physiol Renal Physiol 308: F487-F499, 2015
44. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown Jr. EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Morton Hawkins C; The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669-677, 1992
45. Schieffer B, Bünte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44: 362-368, 2004
46. Brull DJ, Sanders J, Rumley A, Lowe GD, Humphries SE, Montgomery HE: Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart 87: 252-255, 2002
47. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, Koide H: Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am JMed Sci 343: 46-51, 2012
48. Mandelia A, Bajpai M, Agarwala S, Gupta AK, Kumar R, Ali A: The role of urinary TGFb1, TNF-a, IL-6 and microalbuminuria for monitoring therapy in posterior urethral valves. Pediatr Nephrol 28: 1991-2001, 2013
49. Lieberman J: Elevation of serum angiotensinconverting-enzyme (ACE) level in sarcoidosis. Am J Med 59: 365-372, 1975
50. Weinstock JV, Ehrinpreis MN, Boros DL, Gee JB: Effect of SQ 14225, an inhibitor of angiotensin I-converting enzyme, on the granulomatous response to Schistosoma mansoni eggs inmice. J Clin Invest 67: 931-936, 1981
51. Zambidis ET, Park TS, Yu W, Tam A, Levine M, Yuan X, Pryzhkova M, Péault B: Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112: 3601-3614, 2008
52. Gossmann J, Thürmann P, Bachmann T, Weller S, Kachel HG, Schoeppe W, Scheuermann EH: Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. Kidney Int 50: 973-978, 1996
53. Shen XZ, Billet S, Lin C, Okwan-Duodu D, Chen X, Lukacher AE, Bernstein KE: The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol 12: 1078-1085, 2011
54. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA, Fu Y, Chin-Dusting J, Cooper ME, Tikellis C: Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 107: 888-897, 2010
55. Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY: Loss of angiotensin-converting enzyme 2 enhances TGF-b/Smad-mediated renal fibrosis and NF-kB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 92: 650-661, 2012
56. Al-Maghrebi M, Benter IF, Diz DI: Endogenous angiotensin-(1-7) reduces cardiac ischemiainduced dysfunction in diabetic hypertensive rats. Pharmacol Res 59: 263-268, 2009
57. Zhang J, Noble NA, Border WA, Huang Y: Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298: F579-F588, 2010
58. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA, dos Santos RA, Simões e Silva AC, Teixeira MM: Antiinflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 185: 5569-5576, 2010
59. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T: Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One 4: E5406, 2009
60. Crowley SD, Song YS, Sprung G, Griffiths R, Sparks M, Yan M, Burchette JL, Howell DN, Lin EE, Okeiyi B, Stegbauer J, Yang Y, Tharaux PL, Ruiz P: A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin IIdependent hypertension. Hypertension 55: 99-108, 2010
61. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG: Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296: R208-R216, 2009
62. Kato H, Ishida J, Nagano K, Honjo K, Sugaya T, TakedaN, Sugiyama F, Yagami K, Fujita T, Nangaku M, Fukamizu A: Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells. Lab Invest 88: 731-739, 2008
63. Zhang JD, Patel MB, Griffiths R, Dolber PC, Ruiz P, Sparks MA, Stegbauer J, Jin H, Gomez JA, Buckley AF, Lefler WS, Chen D, Crowley SD: Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptormediated kidney fibrosis. J Clin Invest 124: 2198-2203, 2014
64. Zhang JD, Patel MB, Song YS, Griffiths R, Burchette J, Ruiz P, Sparks MA, Yan M, Howell DN, Gomez JA, Spurney RF, Coffman TM, Crowley SD: A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res 110: 1604-1617, 2012
65. Zhang J, Patel MB, Griffiths R, Mao A, Song YS, Karlovich NS, Sparks MA, Jin H, Wu M, Lin EE, Crowley SD: Tumor necrosis factor-a produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension 64: 1275-1281, 2014
66. Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, Davidson JM, Linton MF, Fazio S, Homma T, Yoshida H, Ichikawa I: Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 110: 1859-1868, 2002
67. Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, MajorAS, LintonMF, Fazio S, Hunley TE, Kon V, FogoAB:Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol 300: F1203-F1213, 2011
68. Siragy HM: The angiotensin II type 2 receptor and the kidney. J Renin Angiotensin Aldosterone Syst 11: 33-36, 2010
69. Arendshorst WJ, Brännström K, Ruan X: Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 10[Suppl 11]: S149-S161, 1999
70. Curato C, Slavic S, Dong J, Skorska A, Altarche-Xifró W, Miteva K, Kaschina E, Thiel A, Imboden H, Wang J, Steckelings U, Steinhoff G, Unger T, Li J: Identification of noncytotoxic and IL-10-producing CD8 +AT2R+ T cell population in response to ischemic heart injury. J Immunol 185: 6286-6293, 2010
71. Skorska A, von Haehling S, Ludwig M, Lux CA, Gaebel R, Kleiner G, Klopsch C, Dong J, Curato C, Altarche-Xifró W, Slavic S, Unger T, Steinhoff G, Li J, David R: The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function. J CellMolMed 19: 1975-1985, 2015
72. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M: Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47: 5995-6008, 2004
73. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM: Angiotensin II type 2 receptor stimulation: A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118: 2523-2532, 2008
74. Sabuhi R, Ali Q, Asghar M, Al-Zamily NR, Hussain T: Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: Opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol 300: F700-F706, 2011
75. Dhande I, Ali Q, Hussain T: Proximal tubule angiotensin AT2 receptors mediate an antiinflammatory response via interleukin-10: Role in renoprotection in obese rats. Hypertension 61: 1218-1226, 2013
76. Rompe F, Artuc M, Hallberg A, Alterman M, Ströder K, Thöne-Reineke C, Reichenbach A, Schacherl J, Dahlöf B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM: Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 55: 924-931, 2010
77. Cherney DZ, Reich HN, Scholey JW, Daneman D, Mahmud FH, Har RL, Sochett EB: The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. Diabetologia 56: 2308-2317, 2013
78. Morishita Y, Hanawa S, Chinda J, Iimura O, Tsunematsu S, Kusano E: Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension. Hypertens Res 34: 308-313, 2011
79. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012
80. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
81. Itani HA, McMaster Jr. WG, Saleh MA, Nazarewicz RR, Mikolajczyk TP, Kaszuba AM, Konior A, Prejbisz A, Januszewicz A, Norlander AE, Chen W, Bonami RH, Marshall AF, Poffenberger G, Weyand CM, Madhur MS, Moore DJ, Harrison DG, Guzik TJ: Activation of human T cells in hypertension: Studies of humanized mice and hypertensive humans. Hypertension 68: 123-132, 2016
82. Di Paolo S, SchenaA, Stallone G, Grandaliano G, Soccio M, Cerullo G, Gesualdo L, Paolo Schena F: Captopril enhances transforming growth factor (TGF)-beta1 expression in peripheral blood mononuclear cells: A mechanismindependent fromangiotensin converting enzyme inhibition? A study in cyclosporinetreated kidney-transplanted patients. Transplantation 74: 1710-1715, 2002
83. Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42: 905-910, 2003
84. Sonmez A, Kisa U, Uckaya G, Eyileten T, Comert B, Koc B, Kocabalkan F, Ozata M: Effects of losartan treatment on T-cell activities and plasma leptin concentrations in primary hypertension. J Renin Angiotensin Aldosterone Syst 2: 112-116, 2001
85. Koh KK, Quon MJ, Han SH, ChungWJ, Ahn JY, Seo YH, KangMH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110: 3687-3692, 2004
86. Lopez Santi RG, Valeff EC, Duymovich CR, Mazziotta D, Mijailovsky NE, Filippa GC, Maltez R, Hernandez VA, Monroy AG, Borzi JG, AchemeRA, EtchegoyenMC;PROCORDIS investigators: Effects of an angiotensinconverting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study. Coron Artery Dis 16: 423-429, 2005
87. Di NapoliM, Papa F: Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 34: 2922-2929, 2003
88. Tsuruoka S, Kai H, Usui J, Morito N, Saito C, Yoh K, Yamagata K: Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis. Intern Med 52: 303-308, 2013
89. Kintscher U, Marx N, Martus P, Stoppelhaar M, Schimkus J, Schneider A, Walcher D, Kümmel A, Winkler R, Kappert K, Dörffel Y, Scholze J, Unger T: Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Res Clin Pract 89: 209-215, 2010
90. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ: Comparative effects of angiotensinconverting enzymeinhibitionandangiotensinreceptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 23: 334-342, 2012
91. Sato H, Akai Y, Iwano M, Kurumatani N, Kurioka H, Kubo A, Yamaguchi T, Fujimoto T, Dohi K: Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of systemic lupus erythematosus. Lupus 7: 530-534, 1998
92. Akai Y, Sato H, Iwano M, Kurumatani N, Kurioka H, Kubo A, Yamaguchi T, Shiiki H, Fujimoto T, Dohi K: Association of an insertion polymorphism of angiotensinconverting enzyme gene with the activity of lupus nephritis. Clin Nephrol 51: 141-146, 1999
93. Tavana S, Argani H, Gholamin S, Razavi SM, Keshtkar-JahromiM, Talebian AS, Moghaddam KG, Sepehri Z, Azad TM, Keshtkar-Jahromi M: Influenza vaccination in patients with pulmonary sarcoidosis: Efficacy and safety. Influenza Other Respi Viruses 6: 136-141, 2012
94. Prkacin I, Novak B, Serti-c J, Mrzljak A: Angiotensin-converting enzyme gene polymorphism in patients with systemic lupus. Acta Med Croatica 55: 73-76, 2001
95. Kaufman KM, Kelly J, Gray-McGuire C, Asundi N, Yu H, Reid J, Baird T, Hutchings D, Bruner G, Scofield RH, Moser K, Harley JB: Linkage analysis of angiotensinconverting enzyme(ACE) insertion/deletion polymorphism and systemic lupus erythematosus. Mol Cell Endocrinol 177: 81-85, 2001
96. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA: Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87: 732-738, 2012
97. Ianiro G, Bibbò S, Montalto M, Ricci R, Gasbarrini A, Cammarota G: Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther 40: 16-23, 2014
98. Marthey L, Cadiot G, Seksik P, Pouderoux P, Lacroute J, Skinazi F, Mesnard B, Chayvialle JA, Savoye G, Druez A, Parlier D, Abitbol V, Gompel M, Eoche M, Poncin E, Bobichon R, Colardelle P, Wils P, Salloum H, Peschard S, Zerbib F, Méresse B, Cerf-Bensussan N, Malamut G, Carbonnel F: Olmesartanassociated enteropathy:Resultsof a national survey. Aliment Pharmacol Ther 40: 1103-1109, 2014
99. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; ONTARGET Investigators: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008
100. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892-1903, 2013
101. Titan SM, M Vieira Jr. J, Dominguez WV, Barros RT, Zatz R: ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: A double-blind randomized clinical trial. Clin Nephrol 76: 273-283, 2011
102. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, Papa ML, Bandinelli M, Lisi GF, Chiavarelli M: Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 94: 1630-1637, 2004
103. Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE: Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 15: 211-217, 2004
104. Ayoub MA, Zhang Y, Kelly RS, See HB, Johnstone EK, McCall EA, Williams JH, Kelly DJ, Pfleger KD: Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease. PLoS One 10: E0119803, 2015
105. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B: Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17[Suppl 3]: S218-S225, 2006
106. Yoshida S, Takeuchi T, Kotani T, Yamamoto N, Hata K, Nagai K, Shoda T, Takai S, Makino S, Hanafusa T: Infliximab, a TNF-a inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens 28: 165-169, 2014
107. KoboriH, Prieto-CarrasqueroMC, Ozawa Y, Navar LG: AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension 43: 1126-1132, 2004
108. Woodard LE, Wilson MH: PiggyBac-ing models and new therapeutic strategies. Trends Biotechnol 33: 525-533, 2015
109. Miyagi A, Lu A, Humphreys BD: Gene editing: Powerful new tools for nephrology research and therapy. J Am Soc Nephrol 27: 2940-2947, 2016
110. Zhang J, Rudemiller NP, Patel MB, Wei Q, Karlovich NS, Jeffs AD, Wu M, Sparks MA, Privratsky JR, Herrera M, Gurley SB, Nedospasov SA, Crowley SD: Competing actions of type 1 angiotensin II receptors expressed on T lymphocytes and kidney epithelium during cisplatin-induced AKI. J Am Soc Nephrol 27: 2257-2264, 2016
111. Zhang J, Rudemiller NP, Patel MB, Karlovich NS, Wu M, McDonough AA, Griffiths R, Sparks MA, Jeffs AD, Crowley SD: Interleukin-1 receptor activation potentiates salt reabsorption in angiotensin II-induced hypertension via the NKCC2 co-transporter in the nephron. Cell Metab 23: 360-368, 2016
112. Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, Wang W, Smits G, Tengesdal I, Dinarello CA, Hung AM: IL-1 inhibition and vascular function in CKD [published online ahead of print September 19, 2016]. J Am Soc Nephrol doi: 10.1681/ASN.2016040453
113. Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM: Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res 15: 7398-7404, 2009
114. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM: Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120: 3350-3364, 2010